138736-91-1

Basic information

• Product Name: (1S,2R)-3,3-Dimethoxy-1,2-cyclobutanedicarboxylic Acid Di-L-Menthyl Ester
• Synonyms: (1S,2R)-3,3-Dimethoxy-1,2-cyclobutanedicarboxylic Acid Di-L-Menthyl Ester;(1S,2R)-3,3-DiMethoxy-1,2-cyclobutanedicarboxylic Acid 1,2-Bis[(1R,2S,5R)-5-Methyl-2-(1-Methylethyl)cyclohexyl] Ester;(1S,2R)-3,3-DiMethoxy-1,2-cyclobutanedicarboxylic Acid Di-L-Menthol Ester
• CAS NO: 138736-91-1
• Molecular Formula: C₂₈H₄₈O₆
• Molecular Weight: 480.67712
• Product Categories: Aromatics;Chiral Reagents;Intermediates
• Mol File: 138736-91-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1S,2R)-3,3-Dimethoxy-1,2-cyclobutanedicarboxylic Acid Di-L-Menthyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2R)-3,3-Dimethoxy-1,2-cyclobutanedicarboxylic Acid Di-L-Menthyl Ester(138736-91-1)
• EPA Substance Registry System: (1S,2R)-3,3-Dimethoxy-1,2-cyclobutanedicarboxylic Acid Di-L-Menthyl Ester(138736-91-1)

Safety Data

• Hazardous Substances Data: 138736-91-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 922-69-0 1,1-dimethoxyethylene 
• 34675-24-6 di-L-menthyl fumarate 

Downstream Products

• 138736-92-2 (2S,3R)-(+)-bis[hydroxymethyl]-1,1-dimethoxycyclobutane 
• 132294-16-7 (2S-trans)-2,3-bis[(benzoyloxy)methyl]cyclobutanone 
• 138736-93-3 C₂₂H₂₄O₆ 
• 132294-17-8 <(1S)-(1α,2β,3β)>-3-Hydroxy-1,2-cyclobutanedimethanol 1,2-dibenzoate ester 

Relevant articles and documents

Synthesis of a new chiral bisphosphine ligand, MOCBP, and its use in rhodium(I)-catalyzed asymmetric hydrogenation of a cyclic enamide

A new chiral bisphosphine ligand (6) bearing a cyclobutane framework was readily prepared by using diastereoselective [2 + 2] cycloaddition. Its rhodium(I) complex was found to be an efficient catalyst for the asymmetric hydrogenation of a cyclic enamide, N-acetyl-1-methylene-1,2,3,4-tetrahydroisoquinoline (9), affording (R)-(-)-N-acetylsalsolidine (10) in up to 80.6% ee.

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

A practical asymmetric synthesis of the antiviral agent lobucavir, BMS-180194

A practical synthesis of the antiviral agent lobucavir, [1R-(1α,2β,3α)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]- 6H-purin-6-one (BMS-180194), is described. The key chiral intermediate, [1S-(1α,2β,3α)]-3-hydroxy-1,2-cyclobutanedimethanol, dibenzoate e

An efficient and diastereoselective [2+2] cycloaddition: Convenient and enantioselective route to trans-2',3'-dihydroxymethylcyclobutane nucleoside analogs

An efficient route to (2S-trans)-2,3-bis[(benzoyloxy)methyl]cyclobutanone (3a), a key intermediate in the synthesis of cyclobutane nucleoside analogs, via a novel asymmetric [2+2] cycloaddition, is described.